Transdermal Drug Delivery Systems Market Size, Share | Report 2023-2032
The global transdermal drug delivery system market was surpassed at USD 59.51 billion in 2022 and is expected to hit around USD 183.68 billion by 2032, growing at a CAGR of 11.93% from 2023 to 2032.
Key Pointers
| Report Coverage | Details |
| Market Size in 2022 | USD 59.51 billion |
| Revenue Forecast by 2032 | USD 183.68 billion |
| Growth rate from 2023 to 2032 | CAGR of 11.93% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Novartis AG; Johnson & Johnson; Mylan Pharmaceuticals, Inc.; Boehringer Ingelheim GmbH; Biogel Technology, Inc.; Transdermal Technologies, Inc.; Skyepharma; Watson Pharmaceuticals, Inc.; 3M Company; Noven Pharmaceuticals, Inc.; 4P Therapeutics, LLC; Transdermal Corporation; Echo Therapeutics, Inc. |
The transdermal drug delivery system market is majorly driven by the increasing prevalence of chronic diseases, where conventional drug delivery system, such as oral drugs has lower potency due to the hepatic first-pass metabolism.
The economies opening up and pharma companies constantly working on developing new drugs through a rise in R&D investments are driving the growth of the transdermal drug delivery system market. Increasing awareness and a rise in the allocation of funds towards healthcare by the governments of various countries represent lucrative growth opportunities during the forecast period.
The efficacious nature of these devices can be attributed to the heightened drug diffusion capabilities over conventional routes of drug delivery, namely oral, intravenous, and pulmonary. Additionally, a significant contributor to market growth is the increasing inclination of patients as well as physicians toward pain-free drug delivery, which is further presumed to drive the market demand during the forecast period. These aforementioned factors are expected to widen the scope for growth throughout the forecast period.
Moreover, the rising patient preference for pain-free drug administration has led to a significant surge in the adoption rate of adhesive skin patches that administer drugs, which is anticipated to present the market with high growth potential. In addition, the incorporation of transdermal systems will promote self-reliance in patients through a significant reduction in the frequency of hospital visits and cumulative treatment costs.
The emergence of technological innovations, such as the inclusion of microneedles or mechanical arrays in transdermal patches, is expected to provide the market with lucrative growth opportunities during the coming years. The advancements include modifications in transdermal patch designs, incorporation of pressure-sensitive adhesives, and permeation enhancers, which have resulted in enhanced drug diffusion and increased capacity to hold a greater amount of drug in the reservoir. Moreover, other innovations comprise miniaturized and advanced transdermal patches and reservoir-type transdermal patches, which deliver accurate medication dosage.
Transdermal Drug Delivery Systems Market Segmentations:
| By Technology | By Application |
|
Electroporation Radio Frequency Iontophoresis Microporation Thermal Mechanical arrays Ultrasound Others |
CNS Pain Management Cardiovascular Hormone Immunological Metabolic Gastrointestinal Infection Cancer Others |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Transdermal Drug Delivery Systems Market
5.1. COVID-19 Landscape: Transdermal Drug Delivery Systems Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Transdermal Drug Delivery Systems Market, By Technology
8.1. Transdermal Drug Delivery Systems Market, by Technology, 2023-2032
8.1.1. Electroporation
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Radio Frequency
8.1.2.1. Market Revenue and Forecast (2019-2032)
8.1.3. Iontophoresis
8.1.3.1. Market Revenue and Forecast (2019-2032)
8.1.4. Microporation
8.1.4.1. Market Revenue and Forecast (2019-2032)
8.1.5. Thermal
8.1.5.1. Market Revenue and Forecast (2019-2032)
8.1.6. Mechanical arrays
8.1.6.1. Market Revenue and Forecast (2019-2032)
8.1.7. Ultrasound
8.1.7.1. Market Revenue and Forecast (2019-2032)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2019-2032)
Chapter 9. Global Transdermal Drug Delivery Systems Market, By Application
9.1. Transdermal Drug Delivery Systems Market, by Application, 2023-2032
9.1.1. CNS
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Pain Management
9.1.2.1. Market Revenue and Forecast (2019-2032)
9.1.3. Cardiovascular
9.1.3.1. Market Revenue and Forecast (2019-2032)
9.1.4. Hormone
9.1.4.1. Market Revenue and Forecast (2019-2032)
9.1.5. Immunological
9.1.5.1. Market Revenue and Forecast (2019-2032)
9.1.6. Metabolic
9.1.6.1. Market Revenue and Forecast (2019-2032)
9.1.7. Gastrointestinal
9.1.7.1. Market Revenue and Forecast (2019-2032)
9.1.8. Infection
9.1.8.1. Market Revenue and Forecast (2019-2032)
9.1.9. Cancer
9.1.9.1. Market Revenue and Forecast (2019-2032)
9.1.10. Others
9.1.10.1. Market Revenue and Forecast (2019-2032)
Chapter 10. Global Transdermal Drug Delivery Systems Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Technology (2019-2032)
10.1.2. Market Revenue and Forecast, by Application (2019-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.1.3.2. Market Revenue and Forecast, by Application (2019-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.1.4.2. Market Revenue and Forecast, by Application (2019-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Technology (2019-2032)
10.2.2. Market Revenue and Forecast, by Application (2019-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.2.3.2. Market Revenue and Forecast, by Application (2019-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.2.4.2. Market Revenue and Forecast, by Application (2019-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Technology (2019-2032)
10.2.5.2. Market Revenue and Forecast, by Application (2019-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Technology (2019-2032)
10.2.6.2. Market Revenue and Forecast, by Application (2019-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.3.2. Market Revenue and Forecast, by Application (2019-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.3.3.2. Market Revenue and Forecast, by Application (2019-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.3.4.2. Market Revenue and Forecast, by Application (2019-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Technology (2019-2032)
10.3.5.2. Market Revenue and Forecast, by Application (2019-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Technology (2019-2032)
10.3.6.2. Market Revenue and Forecast, by Application (2019-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.4.2. Market Revenue and Forecast, by Application (2019-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.4.3.2. Market Revenue and Forecast, by Application (2019-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.4.4.2. Market Revenue and Forecast, by Application (2019-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Technology (2019-2032)
10.4.5.2. Market Revenue and Forecast, by Application (2019-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Technology (2019-2032)
10.4.6.2. Market Revenue and Forecast, by Application (2019-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Technology (2019-2032)
10.5.2. Market Revenue and Forecast, by Application (2019-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Technology (2019-2032)
10.5.3.2. Market Revenue and Forecast, by Application (2019-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Technology (2019-2032)
10.5.4.2. Market Revenue and Forecast, by Application (2019-2032)
Chapter 11. Company Profiles
11.1. Novartis AG
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Johnson & Johnson
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Mylan Pharmaceuticals, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Boehringer Ingelheim GmbH
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Biogel Technology, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Transdermal Technologies, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Skyepharma
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Watson Pharmaceuticals, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. 3M Company
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Noven Pharmaceuticals, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers